2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 474

Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Abstract Number: 1675

Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort
Abstract Number: 1674

Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort
Abstract Number: 1896

Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
Abstract Number: 1701

Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
Abstract Number: 92

Lupus Nephritis Serum Induces Neutrophil Chemotaxis Towards Glomerular Endothelial Cells in Vitro
Abstract Number: 2681

Lupus Primary Care Management Practices
Abstract Number: 2107

Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs
Abstract Number: 1990

Luteolin Modulates Glyco-Lipo-Oxidative Protein Modifications and Inhibits Inflammatory Cytokine Release in Human Osteoarthritic Articular Chondrocytes: Comparison with Colchicine
Abstract Number: 141

Lymphocyte Activation Gene 3 Plasma Level Is Increased and Associated with Progression in Early Rheumatoid Arthritis
Abstract Number: 88

Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis
Abstract Number: 1122

Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls
Abstract Number: 2265

Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-Related Uveitis
Abstract Number: 2143

Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Abstract Number: 124

M10, a Small Fragment of the Hepatocyte Growth Factor Receptor, Attenuates Fibrotic Changes in a Murine Model of Scleroderma Lung Disease and in Human Lung Fibroblasts

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].